

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Biosimilar in cancer treatment: Current & future perspective

Sabnam Ara Begum
R.G.Kar Medical College, India

Cancer represents a significant & growing burden on healthcare system. Biological agents are important therapeutic modality for cancer management. But cost barrier is a deterrent factor for wider use of these agents. In the current scenario of increased cancer drug budgets and loss of patent protection on major biological therapies used in oncology, biosimilars offer an important opportunity to provide clinically effective medications at reduced cost. Biosimilars are currently available for use in oncology in the supportive care system. The focus of biosimilar development is likely to switch to agents such as monoclonal antibodies. Though developmental and regulatory challenges are there, biosimilar approved by regulatory authority offer a safe and effective alternative to originator biological therapies. Greater adoption of biosimilar in oncology represents a key approach in reducing cancer drug budgets and improving cancer patient's access to appropriate therapies.

Biography

Sabnam Ara Begum has completed her MBBS from Burdwan University and Diploma in Child Health as well as MD in Pharmacology from West Bengal University of Health Sciences. She is at present working as an Assistant Professor in the Dept. of Pharmacology at R.G. Kar Medical College in Kolkata. She has published more than 5 papers in reputed journals and is guiding the Post graduate students in their research works in the Pharmacology Department.